Skip to main content

Advertisement

Table 1 Clinical characteristics of patients included in the study.

From: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization

  Cohort 1 (n = 312) Cohort 2 (n = 15)
  No. % No. 15
Age at diagnosis     
< 50 yr 197 63% 6 40%
≥ 50 yr 115 37% 9 60%
Treatment year     
Before 1997 125 40% 0 0%
After 1997 187 60% 15 100%
TNM Stage     
I 67 21% 2 13%
II 139 45% 8 53%
III 98 31% 5 33%
IV 8 3% 0 0%
Positive Lymph Nodes     
0 132 42% 5 33%
1-3 83 27% 5 33%
4-9 58 19% 3 20%
≥ 10 35 11% 2 13%
Unavailable 4 1%   
Nuclear Grade     
1 25 8% 8 53%
2 83 27% 7 47%
3 202 65% 0 0%
Unavailable 2 1%   
ER *     
ER+ 190 61% 14 93%
ER- 122 39% 1 7%
HER2*     
HER2+ 74 24% 1 7%
HER2- 238 76% 14 93%
PR*     
PR+ 244 78% 14 93%
PR- 68 22% 1 7%
Treatment     
Neoadjuvant Chemotherapy 31 10% 0 0%
Adjuvant Chemotherapy 220 71% 12 80%
Radiation Therapy 133 43% 8 53%
Hormonal Rx 210 67% 14 93%
No chemotherapy 50 16% 3 20%
  1. *: ER, HER2 and PR status were determined according to microarray data.